blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3938053

EP3938053 - EPITOPE-BASED APPROACH FOR ALLERGY TREATMENTS AND INHIBITORS FOR CROHN'S DISEASE [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  17.12.2021
Database last updated on 24.01.2025
FormerThe international publication has been made
Status updated on  19.09.2020
Most recent event   Tooltip02.08.2024Change - applicantpublished on 04.09.2024  [2024/36]
Applicant(s)For all designated states
Macrogen, Inc.
238 Teheran-ro, Gangnam-gu
Seoul, 06221 / KR
[2024/36]
Former [2022/03]For all designated states
Psomagen, Inc.
1330 Piccard Drive
Rockville, MD 20850 / US
Inventor(s)01 / APTE, Zachary
360 Langton Street, 301
San Francisco, CA 94103 / US
02 / RICHMAN, Jessica
360 Langton Street, 301
San Francisco, CA 94103 / US
03 / ALMONACID, Daniel
360 Langton Street, 301
San Francisco, CA 94103 / US
04 / SAAVEDRA, Mario
360 Langton Street, 301
San Francisco, CA 94103 / US
05 / ARAYA, Ingrid
360 Langton Street, 301
San Francisco, CA 94103 / US
[N/P]
Former [2022/03]01 / APTE, Zachary
San Francisco, CA 94103 / US
02 / RICHMAN, Jessica
San Francisco, CA 94103 / US
03 / ALMONACID, Daniel
San Francisco, CA 94103 / US
04 / SAAVEDRA, Mario
San Francisco, CA 94103 / US
05 / ARAYA, Ingrid
San Francisco, CA 94103 / US
Representative(s)Ostertag & Partner Patentanwälte mbB
Azenbergstraße 35
70174 Stuttgart / DE
[N/P]
Former [2022/03]Boden, Keith McMurray
Vertus Professional Services ltd t/a Vertus
1 Highlands Road
Reigate
Surrey RH2 0LA / GB
Application number, filing date20769559.413.03.2020
[2022/03]
WO2020US22701
Priority number, dateUS201962817621P13.03.2019         Original published format: US 201962817621 P
US201962817564P13.03.2019         Original published format: US 201962817564 P
US201962824095P26.03.2019         Original published format: US 201962824095 P
US201962828074P02.04.2019         Original published format: US 201962828074 P
US201962832811P11.04.2019         Original published format: US 201962832811 P
[2022/03]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2020186190
Date:17.09.2020
Language:EN
[2020/38]
Type: A2 Application without search report 
No.:EP3938053
Date:19.01.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 17.09.2020 takes the place of the publication of the European patent application.
[2022/03]
Search report(s)International search report - published on:US29.10.2020
(Supplementary) European search report - dispatched on:EP20.02.2023
ClassificationIPC:A61P37/08, A61K39/35, C07K14/415, A61K8/64
[2022/03]
CPC:
A61P1/00 (EP,KR); C07K7/08 (EP,KR); A61K39/35 (EP,US);
A61K31/192 (EP); A61K31/40 (EP); A61K31/404 (EP);
A61K31/44 (EP); A61K38/00 (EP,KR); A61P29/00 (KR);
A61P37/04 (EP); A61P37/08 (KR,US); C07C275/42 (EP);
C07D207/337 (EP); C07D209/08 (EP); C07D209/48 (EP);
C07D213/74 (EP); C07D213/79 (EP); C07K14/415 (US);
G01N33/56977 (EP); G01N33/6878 (EP); G16B35/10 (EP);
G01N2333/11 (EP); G01N2333/70539 (EP); G01N2800/065 (EP);
G01N2800/24 (EP); G16B20/50 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/03]
TitleGerman:AUF EPITOP BASIERENDER ANSATZ FÜR ALLERGIEBEHANDLUNGEN UND INHIBITOREN FÜR MORBUS CROHN[2022/03]
English:EPITOPE-BASED APPROACH FOR ALLERGY TREATMENTS AND INHIBITORS FOR CROHN'S DISEASE[2022/03]
French:APPROCHE BASÉE SUR UN ÉPITOPE DE TRAITEMENTS D'ALLERGIE ET INHIBITEURS DE LA MALADIE DE CROHN[2022/03]
Entry into regional phase23.08.2021National basic fee paid 
23.08.2021Search fee paid 
23.08.2021Designation fee(s) paid 
23.08.2021Examination fee paid 
Examination procedure23.08.2021Examination requested  [2022/03]
20.09.2023Amendment by applicant (claims and/or description)
Fees paidRenewal fee
27.02.2022Renewal fee patent year 03
29.03.2023Renewal fee patent year 04
25.03.2024Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XA]WO2013187906  (IMMUNOMIC THERAPEUTICS INC [US], et al) [X] 1,4,7 * SEQ. 7 * [A] 8-15;
 [A]US2016375130  (O'HEHIR ROBYN ELIZABETH [AU], et al) [A] 1,4,7-15 * claims 1, 8-13, 16; table 24 *;
 [A]  - PRICKETT S R ET AL, "Ara h 1 CD4+ T cell epitope-based peptides: candidates for a peanut allergy therapeutic", CLINICAL & EXPERIMENTAL ALLERGY, WILEY INTERSCIENCE, UK, (20130528), vol. 43, no. 6, doi:10.1111/CEA.12113, ISSN 0954-7894, pages 684 - 697, XP071887413 [A] 1,4,7-15 * abstract; table 1;p. 686 *

DOI:   http://dx.doi.org/10.1111/cea.12113
 [A]  - RAMESH MANISH ET AL, "Peanut T-cell epitope discovery: Ara h 1", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, (20160304), vol. 137, no. 6, doi:10.1016/J.JACI.2015.12.1327, ISSN 0091-6749, page 1764, XP029567339 [A] 1,4,7-15 * abstract *

DOI:   http://dx.doi.org/10.1016/j.jaci.2015.12.1327
 [A]  - PIERSMA SANDER R. ET AL, "Proteolytic processing of the peanut allergen Ara h 3", MOLECULAR NUTRITION & FOOD RESEARCH, DE, (20050801), vol. 49, no. 8, doi:10.1002/mnfr.200500020, ISSN 1613-4125, pages 744 - 755, XP055980014 [A] 1,4,7-15 * abstract; par. 4.4 *

DOI:   http://dx.doi.org/10.1002/mnfr.200500020
International search[X]US2017304432  (HEARL WILLIAM [US], et al) [X] 1, 4, 7/1, 7/4, 8/7/1, 8/7/4, 9/8/7/1, 9/8/7/4, 10/8/7/1, 10/8/7/4, 11/10/8/7/1, 11/10/8/7/4, 12/8/7/1, 12/8/7/4, 13/12/8/7/1, 13/12/8/7/4, 14/8/7/1, 14/8/7/4, 15/8/7/1, 15/8/7/4 * ; paragraphs [0009], [0039], [0079], [0085], [0112], [0113]; claims 51, 59 *;
 [A]WO2017186808  (ALLERGY THERAPEUTICS (UK) LTD [GB]) [A] 1, 4, 7-15 * ; entire document *;
 [A]  - JIANG, S et al., "Ara h 3 allergen [Arachis hypogaea]", Protein, (20101123), Database accession no. ADQ53859.1, URL: NCBI, XP055755818 [A] 1, 4, 7-15 * ; page 1 *
 [A]  - PRICKETT, SR et al., "L31 Safety and Tolerability of a Novel Peptide-Based Immunotherapy for Peanut Allergy", The Journal of Allergy and Clinical Immunology, (20190201), vol. 143, no. 2, doi:10.1016/J.JACI. 2018.12.975, page AB431, XP055755808 [A] 1, 4, 7-15
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.